Role of infectious diseases consultants in management of antimicrobial use in hospitals

Clinical Infectious Diseases

Volumn 38, Issue 7, 2004, Pages 934-938

  Sunenshine, Rebecca H ^a   Liedtke, Laura A ^c   Jernigan, Daniel B ^d   Strausbaugh, Larry J ^a,b,c  

^a Division of Pediatric Infectious Diseases   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CARBAPENEM; LIPID; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CONSULTATION; DRUG APPROVAL; DRUG FORMULATION; HEALTH CARE POLICY; HOSPITAL CARE; HUMAN; INFECTION; MEDICAL SOCIETY; MEDICAL SPECIALIST; PHARMACIST; PRIORITY JOURNAL; TEACHING HOSPITAL; COMMUNICABLE DISEASE; DRUG UTILIZATION; FEE; HOSPITAL PHARMACY;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; CONSULTANTS; DRUG UTILIZATION; FEES AND CHARGES; HOSPITALS, TEACHING; HUMANS; PHARMACY SERVICE, HOSPITAL;

EID: 1842613617     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/382358     Document Type: Article

References (22)

1. Woodward RS, Medoff G, Smith MD, Gray JL III. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school- affiliated hospital. Am J Med 1987; 83:817-23.
2. Frank MO, Batteiger BE, Sorensen SJ, et al. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clin Perform Qual Health Care 1997; 5:180-8.
3. John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997; 24:471-85.
4. McGowan JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994; 15:478-43.
5. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999; 43:459-65.
6. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280:1233-7.
7. Executive Committee of the Infectious Diseases Society of America Emerging Infections Network. The Emerging Infections Network: a new venture for the Infectious Diseases Society of America. Clin Infect Dis 1997; 25:34-6.
8. Cordero L, Sananes M, Ayers LW. Bloodstream infections in a neonatal intensive-care unit: 12 years' experience with an antibiotic control program. Infect Control Hosp Epidemiol 1999; 20:242-6.
9. Schlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospilals. Clin Infect Dis 1997; 25:584-99.
10. Rice LB, Eckstein EC, DeVente J, Schlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23:118-24.
11. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA 1996; 275:234-40.
12. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995; 273: 214-9.
13. McGowen, JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5:1033-48.
14. Seppälä H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A Streptococci in Finland. N Engl J Med 1997; 337:441-6.
15. Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ 1996; 313:387-91.
16. White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25:230-9.
17. Murthy R. Implementation of strategies to control antimicrobial resistance. Chest 2001; 119:405S-11S.
18. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). JAMA 1996; 275:206-9.
19. Gómez J, Conde Cavero SJ, Hernández Cardona JL, et al. The influence of the opinion of an infectious disease consultant on the appropriateness of antibiotic treatment in a general hospital. J Antimicrob Chemother 1996; 38:309-14.
20. Sáez-Llorens X, Castrejón De Wong MM, Castaño E, De Suman O, De Morös D, De Atencio I. Impact of an antibiotic restriction policy on hospital expenditures and bacterial susceptibilities: a lesson from a pediatric institution in a developing country. Pediatr Infect Dis J 2000; 19:200-6.
21. Klapp DL, Ramphal R. Antibiotic restriction in hospitals associated with medical schools. Am J Hosp Pharm 1983; 40:1957-60.
22. Chang S, Sievert DM, Hageman JC, et al. Brief report: infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7.